Business Wire

ZCUBE-ZAMBON-RESEARCH

28.2.2024 14:01:33 CET | Business Wire | Press release

Share
Zcube Launches the 2024 Edition of Open Accelerator, an International Acceleration Program Aimed at Life Sciences Startups with Focus on Women's Health and Femtech

Zcube - Zambon Research Venture announces the fifth edition of Open Accelerator, the international acceleration program for high-potential innovative startups in the field of life sciences. Starting this year, the program will focus on the femtech sector and will feature a new format. The initiative, one of the first internationally in terms of focus and invested capital, invites startups and entrepreneurial ideas aimed at developing products and services to address major medical needs and improve women's health and well-being. The targeted therapeutic areas include gynecology, cardiovascular health, oncology, sexual health, endocrinology, gastroenterology, nutrition, autoimmune disorders, mental health, neurology, reproductive health, and more.

The Call for application will open on Friday, March 8, 2024, on the International Women's Day, and will remain open until June 16. At the end of the selection process, up to 5 startups will be identified to receive an investment of €100,000 each, through a SAFE (Simple Agreement for Future Equity) agreement and will have access to a training and mentoring program delivered by experts in the fields of investments, business development, venture capital, intellectual property, regulatory affairs, and market access.

Startups with the highest potential will also have the opportunity to build a partnership with the Zambon group, accelerating their market access phase and commercial positioning on a global scale.

“We are eager to launch the fifth edition of Open Accelerator; we are excited to discover which companies can bring innovative solutions to change the Life Sciences and women’s health sector. The choice to dedicate the 2024 edition to the femtech sector is deliberate: working in unexplored areas can contribute to creating benefits for the global economy. As highlighted by recent studies, bridging this gender gap is essential” - said Giovanni Magnaghi, President of Zcube and Chief Financial Officer of Zambon – “Since 2016, Open Accelerator has allowed us to offer direct access to capital and expertise to new and promising entrepreneurial ideas, thanks to the collaboration with prominent partners participating in the open innovation ecosystem at our scientific campus, OpenZone, where part of the program is hosted”.

The previous four editions of the program selected 46 startups from 23 countries, 8 of which have received up to €100,000 each in seed investment. The winner of the Distinction Award during the last edition of Open Accelerator comes from the femtech sector: Hyivy Health, a Canadian startup developing a medical device for pelvic floor rehabilitation. Founded in 2019 by Canadian entrepreneur Rachel Bartholomew following a diagnosis of cervical cancer, Hyivy Health aims to improve the standard of care for both patients and physicians through a holistic approach. Bartholomew, CEO of Hyivy Health, commented on the launch of the new edition of Open Accelerator: “It is a turning point for the industry. Open Accelerator is one of the first programs to enter this field with resources and real opportunities for femtech startups on a global level”.

“Open Accelerator values the experience of Zcube and best expresses our vision of Zambon as an open company, where open innovation serves as a lever for cultural and entrepreneurial growth for both us and the entire system” - commented Elena Zambon, President of Zambon and creator of Open Accelerator – “Women's health is a fundamental focus for Zambon and a central issue in international health agendas: supporting these entities and helping them bringing their innovative entrepreneurial ideas to market is an additional effort by our group to innovate cure and care to make patients’ lives better”.

Coordinating Open Accelerator will be a team of professionals experienced in Life Sciences and Venture Capital including Federica Destro, External Innovation & Community manager at Zcube, Vittoria Pavoncello, Technology Scouting & Investment Specialist at Zcube, Michele Gaiotto, CEO of HTH and Advisor to Zcube, and Marco Gullà, Investment Associate at HTH.

For more information about the program, visit www.openaccelerator.it/

For more information about Zcube, visit www.zambon.com/en/innovation/zcube

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240226030549/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye